Seroprevalence and Vaccination Rate of Hepatitis B Virus and Varicella-zoster Virus Among Medical Students Under Immunizing Program

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06901362

Enrollment

401

Registered

2025-03-28

Start date

2025-04-01

Completion date

2025-11-30

Last updated

2025-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Healthy Adult

Keywords

hepatitis B virus, varicella-zoster virus, vaccination, immunizing program, medical students

Brief summary

This study is a cross-sectional study. The study aims to determine the levels of immunity against hepatitis B virus and varicella-zoster virus in medical students.

Detailed description

This study is a cross-sectional study aimed at determining the levels of immunity against the hepatitis B virus and varicella virus in medical students. Additionally, it aims to compare the rate of increase in immunity levels before and after receiving the hepatitis B and varicella-zoster vaccines in medical students. Medical students aged 18 years or older are included in the study.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Medical students * Age 18 years or older

Exclusion criteria

* Known cases of hepatitis B virus infection * Known cases of varicella-zoster virus infection

Design outcomes

Primary

Measure	Time frame	Description
The seroprevalence of hepatitis B virus	From enrollment to the end of treatment at 6 months	The immunity level against the hepatitis B virus is assessed.
The seroprevalence of varicella-zoster virus	From enrollment to the end of treatment at 6 months	The immunity level against varicella-zoster virus is assessed.

Secondary

Measure	Time frame	Description
The vaccination rate of varicella-zoster virus	From enrollment to the end of treatment at 6 months	The vaccination rate of varicella-zoster virus is assessed.
The vaccination rate of hepatitis B virus	From enrollment to the end of treatment at 6 months	The vaccination rate of hepatitis B virus is assessed.

Countries

Thailand

Outcome results